Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1062735 | PMC |
| http://dx.doi.org/10.1172/JCI103666 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Hypertension : what's new in 2024].
Rev Med Suisse
January 2025
Service de néphrologie et d'hypertension, Centre hospitalier universitaire vaudois, 1005 Lausanne.
The major clinical studies in 2024 reviewed in this manuscript will focus on blood pressure measurement, the effect of coffee on the latter, its follow-up in the postpartum period, blood pressure targets for patients at high cardiovascular risk, particularly those with diabetes, and the late onset of primary aldosteronism after a negative initial confirmation test.
View Article and Find Full Text PDF[Prevalent secondary hypertension: a call to strengthen systematic screen for diagnosis and treatment].
Zhonghua Xin Xue Guan Bing Za Zhi
January 2025
Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai200025, China.
Integrative bioinformatics approach identifies novel drug targets for hyperaldosteronism, with a focus on SHMT1 as a promising therapeutic candidate.
Sci Rep
January 2025
Department of Endocrinology, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88, Jiefang Road, Shangcheng District, Hangzhou, 310000, Zhejiang Province, China.
Primary aldosteronism (PA), characterized by autonomous aldosterone overproduction, is a major cause of secondary hypertension with significant cardiovascular complications. Current treatments mainly focus on symptom management rather than addressing underlying mechanisms. This study aims to discover novel therapeutic targets for PA using integrated bioinformatics and experimental validation approaches.
View Article and Find Full Text PDFMetyrapone single administration, as a possible predictive tool of its dosage and timing in Cushing's syndrome.
Front Endocrinol (Lausanne)
January 2025
Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Hospital, Kobe, Japan.
Metyrapone is commonly used in the initial management of Cushing's syndrome to reduce hypercortisolemia, but its optimal dosage and timing can vary significantly between patients. Currently, there are limited guidelines on adjustment methods for its administration to individual needs. This study aimed to evaluate responsiveness of each patient to metyrapone and identify the patient characteristics associated with the indices of cortisol responsiveness following a low-dose metyrapone.
View Article and Find Full Text PDFLiquorice-induced pseudohyperaldosteronism: a rare cause for severe hypertension.
BMJ Case Rep
January 2025
SUT Hospital, Thiruvananthapuram, Kerala, India.
This case report describes an adult man in his 50s with a history of type 2 diabetes and previously well-controlled hypertension, who presented with uncontrolled hypertension, muscle weakness and fatigue. Biochemical testing revealed hypokalaemia. There was no evidence of renal/renovascular disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!